179 related articles for article (PubMed ID: 21569129)
1. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
[TBL] [Abstract][Full Text] [Related]
2. Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?
Jensen-Jarolim E; Singer J
Clin Exp Allergy; 2011 Oct; 41(10):1337-40. PubMed ID: 21545551
[No Abstract] [Full Text] [Related]
3. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.
Shiung YY; Chiang CY; Chen JB; Wu PC; Hung AF; Lu DC; Pan RL; Chang TW
Immunobiology; 2012 Jul; 217(7):676-83. PubMed ID: 22226669
[TBL] [Abstract][Full Text] [Related]
4. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
Karagiannis SN; Bracher MG; Hunt J; McCloskey N; Beavil RL; Beavil AJ; Fear DJ; Thompson RG; East N; Burke F; Moore RJ; Dombrowicz DD; Balkwill FR; Gould HJ
J Immunol; 2007 Sep; 179(5):2832-43. PubMed ID: 17709497
[TBL] [Abstract][Full Text] [Related]
5. The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses.
Moñino-Romero S; Erkert L; Schmidthaler K; Diesner SC; Sallis BF; Pennington L; Jardetzky T; Oettgen HC; Bohle B; Fiebiger E; Szépfalusi Z
Allergy; 2019 Feb; 74(2):236-245. PubMed ID: 30030936
[TBL] [Abstract][Full Text] [Related]
6. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
[TBL] [Abstract][Full Text] [Related]
7. Review: Diagnostic and therapeutic applications of rat basophilic leukemia cells.
Rashid A; Sadroddiny E; Ye HT; Vratimos A; Sabban S; Carey E; Helm B
Mol Immunol; 2012 Oct; 52(3-4):224-8. PubMed ID: 22750069
[TBL] [Abstract][Full Text] [Related]
8. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.
Gould HJ; Mackay GA; Karagiannis SN; O'Toole CM; Marsh PJ; Daniel BE; Coney LR; Zurawski VR; Joseph M; Capron M; Gilbert M; Murphy GF; Korngold R
Eur J Immunol; 1999 Nov; 29(11):3527-37. PubMed ID: 10556807
[TBL] [Abstract][Full Text] [Related]
9. An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.
Wigginton SJ; Furtado PB; Armour KL; Clark MR; Robins A; Emara M; Ghaemmaghami AM; Sewell HF; Shakib F
Clin Exp Allergy; 2008 Feb; 38(2):313-9. PubMed ID: 18070161
[TBL] [Abstract][Full Text] [Related]
10. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells.
Luiten RM; Warnaar SO; Schuurman J; Pasmans SG; Latour S; Daëron M; Fleuren GJ; Litvinov SV
Hum Antibodies; 1997; 8(4):169-80. PubMed ID: 9395919
[TBL] [Abstract][Full Text] [Related]
11. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
Spicer J; Basu B; Montes A; Banerji U; Kristeleit R; Miller R; Veal GJ; Corrigan CJ; Till SJ; Figini M; Canevari S; Barton C; Jones P; Mellor S; Carroll S; Selkirk C; Nintos G; Kwatra V; Funingana IG; Doherty G; Gould HJ; Pellizzari G; Nakamura M; Ilieva KM; Khiabany A; Stavraka C; Chauhan J; Gillett C; Pinder S; Bax HJ; Josephs DH; Karagiannis SN
Nat Commun; 2023 Jul; 14(1):4180. PubMed ID: 37491373
[TBL] [Abstract][Full Text] [Related]
12. An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.
Josephs DH; Nakamura M; Bax HJ; Dodev TS; Muirhead G; Saul L; Karagiannis P; Ilieva KM; Crescioli S; Gazinska P; Woodman N; Lombardelli C; Kareemaghay S; Selkirk C; Lentfer H; Barton C; Canevari S; Figini M; Downes N; Dombrowicz D; Corrigan CJ; Nestle FO; Jones PS; Gould HJ; Blower PJ; Tsoka S; Spicer JF; Karagiannis SN
Allergy; 2018 Dec; 73(12):2328-2341. PubMed ID: 29654623
[TBL] [Abstract][Full Text] [Related]
13. Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.
Josephs DH; Bax HJ; Lentfer H; Selkirk C; Spicer JF; Karagiannis SN
Lancet; 2015 Feb; 385 Suppl 1():S53. PubMed ID: 26312875
[TBL] [Abstract][Full Text] [Related]
14. Functions of dendritic-cell-bound IgE in allergy.
Platzer B; Stout M; Fiebiger E
Mol Immunol; 2015 Dec; 68(2 Pt A):116-9. PubMed ID: 26052071
[TBL] [Abstract][Full Text] [Related]
15. Acid Stripping of Surface IgE Antibodies Bound to FcεRI is Unsuitable for the Functional Assays that Require Long-Term Culture of Basophils and Entire Removal of Surface IgE.
Galeotti C; Karnam A; Das M; Kaveri SV; Bayry J
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31941161
[TBL] [Abstract][Full Text] [Related]
16. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge.
Christensen LH; Holm J; Lund G; Riise E; Lund K
J Allergy Clin Immunol; 2008 Aug; 122(2):298-304. PubMed ID: 18572230
[TBL] [Abstract][Full Text] [Related]
17. Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome.
Bax HJ; Chauhan J; Stavraka C; Khiabany A; Nakamura M; Pellizzari G; Ilieva KM; Lombardi S; Gould HJ; Corrigan CJ; Till SJ; Katugampola S; Jones PS; Barton C; Winship A; Ghosh S; Montes A; Josephs DH; Spicer JF; Karagiannis SN
Cells; 2020 Jul; 9(7):. PubMed ID: 32645919
[TBL] [Abstract][Full Text] [Related]
18. Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3.
Okoshi Y; Tahara-Hanaoka S; Nakahashi C; Honda S; Miyamoto A; Kojima H; Nagasawa T; Shibuya K; Shibuya A
Int Immunol; 2005 Jan; 17(1):65-72. PubMed ID: 15569773
[TBL] [Abstract][Full Text] [Related]
19. Use of Engineered Nanoparticles (ENPs) for the Study of High-Affinity IgE FcεRI Receptor Engagement and Rat Basophilic Leukemia (RBL) Cell Degranulation.
Alelwani W; Alharbi RA; Wan D; Vllasaliu D; Falcone FH; Stolnik S
Methods Mol Biol; 2020; 2163():171-180. PubMed ID: 32766975
[TBL] [Abstract][Full Text] [Related]
20. Syk and Lyn mediate distinct Syk phosphorylation events in FcɛRI-signal transduction: implications for regulation of IgE-mediated degranulation.
Sanderson MP; Wex E; Kono T; Uto K; Schnapp A
Mol Immunol; 2010; 48(1-3):171-8. PubMed ID: 20828828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
